Resumen: Early detection of clinically significant prostate cancer (csPCa) has improved since the introduction of magnetic resonance imaging (MRI) and guided biopsies for this purpose; however, suspicion of PCa is still based on elevated serum prostate-specific antigen and/or abnormal digital rectal examination. At present, the decision to perform a prostate biopsy primarily depends on the Prostate Imaging-Reporting and Data System (PI-RADS) score for lesions observed on MRI. Prostate biopsy is typically avoided when negative MRI (PI-RADS <3) is reported owing to its high negative predictive value; nevertheless, uncertain scenarios remain... Idioma: Inglés DOI: 10.1016/j.euros.2022.06.002 Año: 2022 Publicado en: European urology open science 42 (2022), 40-41 ISSN: 2666-1691 Factor impacto JCR: 2.5 (2022) Categ. JCR: UROLOGY & NEPHROLOGY rank: 51 / 88 = 0.58 (2022) - Q3 - T2 Factor impacto CITESCORE: 1.7 - Medicine (Q3)